Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy May 26, 2026
Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update May 7, 2026
Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update March 6, 2026
Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference January 5, 2026
Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update November 13, 2025
Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025 November 8, 2025